These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35193824)

  • 1. Nonclinical and quality assessment of cell therapy products: Report on the 4th Asia Partnership Conference of Regenerative Medicine, April 15, 2021.
    Yoneda T; Tanaka T; Bando K; Choi BH; Chang R; Fujiwara Y; Gupta PK; Ham DS; Karasawa H; Kuwae S; Lee SM; Moriya Y; Takakura K; Tsurumaki Y; Watanabe T; Yoshimura K; Nomura M
    Cytotherapy; 2022 Sep; 24(9):892-904. PubMed ID: 35193824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-clinical, quality and environmental impact assessments of cell and gene therapy products: Report on the 5th Asia Partnership Conference of Regenerative Medicine - April 7, 2022.
    Tanaka T; Karasawa H; Yasumoto M; Choi BH; Chang R; Komuro M; Miyano M; Moriya Y; Muthusamy S; Okubo S; Takakura K; Tsurumaki Y; Watanabe T; Wen K; Yoneda T; Yuan TT; Nomura M
    Cytotherapy; 2023 Jul; 25(7):683-698. PubMed ID: 37097265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-clinical assessment of cell therapy products: the perspective from five Asian countries/regions based on regulatory guidelines and the underpinning rationales.
    Yoneda T; Choi BH; Gupta PK; Ho CY; Tsui YP; Wang LM; Fujiwara Y; Karasawa H; Moriya Y; Bando K; Kamiyama Y; Kanki M; Omura K; Watanabe T; Bae Y; Chou FC; Ham DS; Lee JY; Liu G; Liu Y; Ooi J; Tsurumaki Y
    Cytotherapy; 2021 Oct; 23(10):874-885. PubMed ID: 34116946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory systems and requirements for clinical trials of AAV-based gene therapies - Perspectives from six Asian countries or regions: Report from the 6th Asia Partnership Conference of Regenerative Medicine - April 20, 2023.
    Mizoguchi H; Zhang AJ; Gupta PK; Komuro M; Cheun WK; Chiu CW; Choi B
    Regen Ther; 2024 Jun; 26():334-345. PubMed ID: 39036442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gaps between Asian regulations for eligibility of human mesenchymal stromal cells as starting materials of cell therapy products and comparability of mesenchymal stromal cell-based products subject to changes in their manufacturing process.
    Tanaka T; Lee SM; Mikami M; Yokota K; Takakura K
    Regen Ther; 2020 Dec; 15():265-273. PubMed ID: 33426228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of international guidelines for regenerative medicine: Knee cartilage repair and replacement using human-derived cells and tissues.
    Itoh K; Kano S
    Biologicals; 2016 Jul; 44(4):267-270. PubMed ID: 27156144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Current status of the regulation and development of cell therapy products in Japan].
    Igarashi Y; Sato Y
    Nihon Yakurigaku Zasshi; 2018; 151(6):254-259. PubMed ID: 29887575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical Toxicity Studies for Regenerative Medicine in Japan.
    Shigeto J; Ichiki T; Nii T; Konno K; Nakanishi Y; Sugiyama D
    Clin Ther; 2018 Nov; 40(11):1813-1822. PubMed ID: 30458928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Translational/regulatory science researches of NIHS for regenerative medicine and cellular therapy products].
    Sato Y
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2014; (132):6-9. PubMed ID: 25707195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory Aspects of Cell and Gene Therapy Products: The Japanese Perspective.
    Maruyama Y; Noda S; Okudaira S; Sakurai A; Okura N; Honda F
    Adv Exp Med Biol; 2023; 1430():155-179. PubMed ID: 37526847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of guidelines for biological ancillary materials used for the manufacture of gene and cellular therapy products in Asia.
    Tanaka T; Yoshimura K; Chang R; Choi B; Gai Y; Gupta PK; Kolkundkar U; Lee SM; Lee S; Liao W; Zhao X; Takakura K
    Cytotherapy; 2023 Feb; 25(2):220-228. PubMed ID: 36274006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory Frameworks for Gene and Cell Therapies in Japan.
    Maeda D; Yamaguchi T; Ishizuka T; Hirata M; Takekita K; Sato D
    Adv Exp Med Biol; 2015; 871():147-62. PubMed ID: 26374217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conference scene. A bright future for tissue engineering and regenerative medicine in the Asia Pacific region.
    Frith JE; Hudson JE; Cooper-White JJ
    Regen Med; 2011 Mar; 6(2):167-70. PubMed ID: 21391850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Report of the international conference on manufacturing and testing of pluripotent stem cells.
    Abbot S; Agbanyo F; Ahlfors JE; Baghbaderani BA; Bartido S; Bharti K; Burke C; Carlsson B; Cavagnaro J; Creasey A; DiGiusto D; Francissen K; Gaffney A; Goldring C; Gorba T; Griffiths E; Hanatani T; Hayakawa T; Heki T; Hoogendoorn K; Kawamata S; Kimura H; Kirkeby A; Knezevic I; Lebkowski J; Lin S; Lin-Gibson S; Lubiniecki A; O'Shea O; Pera M; Petricciani J; Pigeau G; Ratcliffe A; Sato Y; Schumann GG; Shingleton W; Stacey Chair G; Sullivan S; Svendsen CN; Trouvin JH; Vandeputte J; Yuan BZ; Zoon K
    Biologicals; 2018 Nov; 56():67-83. PubMed ID: 30150108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishment of the National Consortium for Regenerative Medicine and National Regenerative Medicine Database in Japan.
    Okada K; Sato Y; Sugiyama D; Sawa Y
    Clin Ther; 2018 Jul; 40(7):1076-1083. PubMed ID: 29958729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Industrialization of regenerative medicine in Japan].
    Sugawara K; Hata K
    Clin Calcium; 2008 Dec; 18(12):1751-6. PubMed ID: 19043189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulatory perspectives of Japan.
    Kusakabe T
    Biologicals; 2015 Sep; 43(5):422-4. PubMed ID: 26028474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Report of the International Regulatory Forum on Human Cell Therapy and Gene Therapy Products.
    Hayakawa T; Harris I; Joung J; Kanai N; Kawamata S; Kellathur S; Koga J; Lin YC; Maruyama Y; McBlane J; Nishimura T; Renner M; Ridgway A; Salmikangas P; Sakamoto N; Sato D; Sato Y; Toda Y; Umezawa A; Werner M; Wicks S
    Biologicals; 2016 Sep; 44(5):467-79. PubMed ID: 27461129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Japanese Regulatory Frameworks for Clinical Research and Marketing Authorization of Gene Therapy and Cellular Therapy Products.
    Nagai S; Ozawa K
    Curr Gene Ther; 2017; 17(1):17-28. PubMed ID: 28382858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accelerating Cell Therapy for Stroke in Japan: Regulatory Framework and Guidelines on Development of Cell-Based Products.
    Houkin K; Shichinohe H; Abe K; Arato T; Dezawa M; Honmou O; Horie N; Katayama Y; Kudo K; Kuroda S; Matsuyama T; Miyai I; Nagata I; Niizuma K; Sakushima K; Sasaki M; Sato N; Sawanobori K; Suda S; Taguchi A; Tominaga T; Yamamoto H; Yamashita T; Yoshimine T;
    Stroke; 2018 Apr; 49(4):e145-e152. PubMed ID: 29581346
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.